Scholar Rock Holding Corp (SRRK) Stock Price & News

SRRK:NASDAQ

Scholar Rock Holding Corp

$55.41

-0.47%

(-0.26) 1D

$61.97

+11.84% (+6.56)

After hours

Closed: Sep 11, 4:00:00 PM GMT-4 · USD

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for SRRK...

Open

$55.67

High

$56.94

Low

$54.91

Mkt. cap

6.75B

Avg. vol.

1.11M

Volume

994.40K

52-wk high

$61.75

52-wk low

$27.07

EPS

-$3.30

Beta

0.67

Shares outstanding

121.78M

No. of employees

289

Open

$55.67

High

$56.94

Low

$54.91

Mkt. cap

6.75B

Avg. vol.

1.11M

Volume

994.40K

52-wk high

$61.75

52-wk low

$27.07

EPS

-$3.30

Beta

0.67

Shares outstanding

121.78M

No. of employees

289

Related stocks

Madrigal Pharmaceuticals Inc

$534.49

+0.26%

RYTM

Rhythm Pharmaceuticals Inc

$104.71

+2.46%

DFTX

Definium Therapeutics Inc

$38.89

+3.07%

News stories

From web sources and news partners

Stocktwits

11 hours ago

Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours

GuruFocus

11 hours ago

Scholar Rock (SRRK) Gains FDA Approval for Isembyld Amid High Pr

Reuters

12 hours ago

Scholar Rock gets first FDA nod for rare muscle-wasting disease

TradingView

1 day ago

SRRK: Apitegromab nears FDA approval with robust demand, global expansion, and a strong market position

About Scholar Rock Holding Corp

CEO-

Employees289

Founded2012

Headquarters-

SectorBiotechnology

Websitescholarrock.com

Analyst	Recommendation	Action	Price target	Projected	Date
Evan Seigerman BMO Capital	Buy	Maintained	$76.00	+37.2%	09/10/2026
Andres Y. Maldonado H.C. Wainwright	Buy	Reiterated	$65.00	+17.3%	09/08/2026
David Nierengarten Wedbush	Buy	Maintained	$64.00	+15.5%	08/21/2026
Gary Nachman Canaccord Genuity	Buy	Reiterated	$62.00	+11.9%	08/12/2026
Tessa Romero J.P. Morgan	Buy	Reiterated	$63.00	+13.7%	08/13/2026
Unknown Analyst Wedbush	Buy	Maintained	$58.00	+4.7%	08/10/2026
Marc Frahm TD Cowen	Buy	Maintained	-	-	08/09/2026
Cory Kasimov Evercore ISI	Buy	Maintained	$65.00	+17.3%	08/07/2026
Srikripa Devarakonda Truist Financial	Buy	Reiterated	-	-	08/07/2026
Geoff Meacham Citi	Buy	Maintained	$60.00	+8.3%	08/07/2026
Tazeen Ahmad Bank of America Securities	Buy	Reiterated	$58.00	+4.7%	08/07/2026
Etzer Darout Barclays	Buy	Maintained	$55.00	-0.7%	08/07/2026
Unknown Analyst Leerink Partners	Buy	Maintained	$59.00	+6.5%	07/17/2026
Unknown Analyst Canaccord Genuity	Buy	Initiated	$62.00	+11.9%	04/20/2026
Amy Li Jefferies	Buy	Maintained	$57.00	+2.9%	04/01/2026
Martin Auster Raymond James	Buy	Reiterated	$60.00	+8.3%	03/30/2026
Eric Schmidt FCA Cantor Fitzgerald	Buy	Maintained	-	-	03/19/2026
Allison Bratzel Piper Sandler	Buy	Maintained	$58.00	+4.7%	03/04/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	50.49M	46.88M	51.81M	58.23M
Cost of revenue	50.49M	46.88M	51.81M	58.23M
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	53.06M	45.02M	50.20M	50.67M
Operating expense	53.06M	45.02M	50.20M	50.67M
Total operating expenses	103.55M	91.90M	102.02M	108.90M
Operating income	-103.55M	-91.90M	-102.02M	-108.90M
Other non operating income	-69.00K	-61.00K	-790.00K	-570.00K
EBT including unusual items	-102.22M	-90.96M	-105.51M	-109.90M
EBT excluding unusual items	-102.22M	-90.96M	-102.17M	-109.90M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-102.22M	-90.96M	-105.51M	-109.90M
Net profit margin	-	-	-	-
Earnings per share	-0.90	-0.88	-0.83	-0.84
Interest and investment income	2.73M	3.53M	2.94M	4.09M
Interest expense	-1.33M	-2.53M	-2.30M	-4.52M
Net interest expenses	1.40M	992.00K	633.00K	-425.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	-103.13M	-91.47M	-101.68M	-108.60M
Gain or loss from assets sale	-	-	3.00K	-

Finance

Ask anything